DOCSLIB.ORG

Triptans for the Treatment of Acute Migraines in Adults: a Systematic Review and Network Meta- Analysis (ONLINE APPENDICES)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Triptans for the Treatment of Acute Migraines in Adults: a Systematic Review and Network Meta- Analysis (ONLINE APPENDICES) Triptans for the Treatment of Acute Migraines in Adults: A Systematic Review and Network Meta- Analysis (ONLINE APPENDICES) George Wells, Shannon Kelly, Chris Cameron, Meghan Murphy, Shu-Ching Hsieh, Ahmed Kotb, Joan Peterson, Li Chen, Vijay Shukla, Becky Skidmore February 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca [email protected] 2 APPENDICES Appendix A: Review of Previous Evidence Syntheses Author, Interventions Comparators Studies Major Conclusion(s) Notes Publication Date Included (n) Thorlund et al. Oral triptan Oral triptan or 74 Efficacy: Triptans appear to Industry-funded 2013(11) placebo offer differing treatment Only included: effects. Eletriptan Double blind RCTs consistently has the highest Oral formulations odds of producing headache Excluded: relief at 2 hours, freedom Patients with history from pain at 2 hours, of treatment- sustained headache relief at resistant migraines 24 hours, and sustained (i.e. previous poor freedom from pain at 24 response to a hours. triptan) Had other clinical Rizatriptan, zolmitriptan, and significant high-dose (100 mg) Illnesses sumatriptan also appear effective at two hours, No menstrual whereas only zolmitriptan migraines and high-dose sumatriptan No safety appear to maintain their efficacy at 24 hours. Ontario Drug Policy Research Network Ontario Drug Policy Research Network 3 Worthington Triptans Varied by Twelve acute medications Limited literature 2013 (1) comparison, received a strong search with limited mix of recommendation for use in transparency of SR/MA and acute migraine therapy methods, no RCT (almotriptan, eletriptan, information frovatriptan, naratriptan, scientist used in the rizatriptan, sumatriptan, literature search zolmitriptan, ASA, ibuprofen, conduct, unsure of naproxen sodium, diclofenac data synthesis potassium, and methods, primary acetaminophen). Four RCTs used only received a weak where existing SR or recommendation for use MA was not (dihydroergotamine, available (no ergotamine, codeine- indication of containing combination whether the quality analgesics, and tramadol- of the SR/MAs used containing combination was assessed), no analgesics). Three of these indirect were not recommended for comparisons routine use (ergotamine, and conducted. codeine- and tramadol- containing medications). Strong recommendations were made to avoid use of butorphanol and butalbital- containing medications. NICE, Triptan Triptan, 19 Offer combination therapy Included 2013(7) antiemetics, with an oral triptan and an adolescents 12 to aspirin, NSAIDs, NSAID, or an oral triptan and 18, Placebo not opioids, acetaminophen, for the included as acetaminophen, acute treatment of migraine, comparator. triptans, ergots taking into account the and person's preference, NMA limited corticosteroids comorbidities and risk of outcomes to: adverse events. For young headache response people aged 12–17 years up to 2 hours; consider a nasal triptan in freedom from pain preference to an oral triptan. up to 2 hours; For women and girls with sustained headache predictable menstrual- response at 24 related migraine that do not hours and sustained respond adequately to freedom from pain standard acute treatment, at 24 hours, change consider treatment with in patient reported frovatriptan (2.5 mg twice a migraine days. day) or zolmitriptans (2.5 mg twice or three times a day) Triptans generally on the days migraine is studied as a class in expected. the NMA, only separately in a few analyses Ontario Drug Policy Research Network Ontario Drug Policy Research Network 4 Asseburg et al. Oral Triptan at Oral triptan at 56 Efficacy and safety: The Update of a 2012(8) listed dosing listed dosing or highest probability of 2-hour previous review placebo pain-free was estimated for (Ferrari 2000) eletriptan 40 mg and the Two databases lowest probability of searched recurrence was estimated for naratriptan 2.5 mg. The probability of achieving sustained pain-free and no adverse events was estimated to be highest with eletriptan 40 mg. Cochrane Various – Head to head Triptans studied (numerous)(137- single drug with similar or individually 150) formulation placebo or combination Helfand 2009(9, Triptans (oral, Triptans (oral, 98 There is no consistent NMA only 10) nasal, and nasal, and evidence that one triptan has conducted where injectable injectable or any particular advantage or there were no head- placebo disadvantage over another in to-head any subgroup based on age, comparisons and race, gender, prophylactic where there was a treatment, or menstruation- common associated migraine. intervention across studies. Otherwise standard meta- analysis and qualitative review done. Ontario Drug Policy Research Network Ontario Drug Policy Research Network 5 Appendix B: Detailed Literature Search Strategy Triptans – Acute Migraines – Final Strategies 2013 Oct 6 Database: Embase Classic+Embase <1947 to 2013 October 04>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present> Search Strategy: -------------------------------------------------------------------------------- 1 exp Migraine Disorders/ (66228) 2 (migrain* or migran*).tw. (89392) 3 (anti-migrain* or antimigrain* or anti-migran* or antimigran*).tw. (2360) 4 sick headache*.tw. (31) 5 or/1-4 (106437) 6 exp Tryptamines/ (86272) 7 (tryptamin* or tryptomin* or triptan* or indolylethylamine* or NSC 73938 or NSC73938).tw. (10838) 8 ("BRN 0125513" or CCRIS 8959 or EINECS 200-510-5 or Indol-3-ethylamine or UNII-422ZU9N5TV).tw. (0) 9 Tryptamines.rn. (4631) 10 (almotriptan* or Almogran or Almotrex or Amignul or Axert or PNU 180638E or PNU-180638E or UNII- PJP312605E).tw. (681) 11 almotriptan.rn. (1149) 12 (eletriptan* or Relpax or Relert or Relepax or "UK 116044" or "UK 116,044" or "UK-116044" or "UK-116,044" or UNII-22QOO9B8KI).tw. (686) 13 eletriptan.rn. (1281) 14 (frovatriptan* or Allegro or Frova or Frovelan or Migard or Miguard or SB 209509 or VML-251 or VML251).tw. (927) 15 frovatriptan.rn. (872) 16 (naratriptan* or Amerge or Colatan or Naragran or Naramig or UNII-QX3KXL1ZA2).tw. (841) 17 naratriptan.rn. (1619) 18 (rizatriptan* or Risatriptan* or "L 705,126" or "L 705126" or "L-705,126" or "L-705126" or Maxalt or "MK 0462" or MK 462 or MK-0462 or MK-462 or rizalief or rizalt or rizaliv or UNII-51086HBW8G).tw. (1299) 19 rizatriptan.rn. (2190) 20 (sumatriptan* or Arcoiran or Alsuma or BRN 6930870 or Diletan or Dolmigral or GR 43175 or GR 43175X or GR-43175 or HSDB 7742 or Imigran* or Imiject or Imitrex or micranil or Migril or Novelian or Sumigrene or Suminat or Sumatran or Sumatriptanum or Sumax or UNII-8R78F6L9VO or Zecuity).tw. (6824) 21 sumatriptan.rn. (8795) 22 (Zolmitriptan* or AscoTop or Flezol or Rapimelt or UNII-2FS66TH3YW or Zolmitriptan or Zomig or Zomig-ZMT or Zomigon or Zomigoro).tw. (1407) 23 Zolmitriptan.rn. (2644) 24 (Treximet or Trexima).tw. (60) 25 or/6-24 (102640) 26 5 and 25 (11117) 27 randomized controlled trial.pt. (387867) 28 exp randomized controlled trials as topic/ (142502) 29 random allocation/ (145233) 30 double-blind method/ or single-blind method/ (289667) 31 Placebos/ (277057) 32 (random* or RCT$1 or placebo*).tw. (1760512) 33 ((singl* or doubl* or trebl* or tripl*) and (mask* or blind* or dumm*)).tw. (332772) 34 or/27-33 (2166102) 35 26 and 34 (2796) 36 adult.mp. (9410610) Ontario Drug Policy Research Network Ontario Drug Policy Research Network 6 37 middle aged.sh. (4500001) 38 age$.tw. (5885873) 39 or/36-38 (14388970) 40 35 and 39 (1651) 41 exp Animals/ not (exp Animals/ and Humans/) (8923948) 42 40 not 41 (1647) 43 (comment or editorial or interview or letter or news).pt. (2770847) 44 42 not 43 (1638) 45 limit 44 to english language (1599) 46 45 use prmz (705) 47 exp migraine/ (66228) 48 (migrain* or migran*).tw. (89392) 49 (anti-migrain* or antimigrain* or anti-migran* or antimigran*).tw. (2360) 50 sick headache*.tw. (31) 51 or/47-50 (106437) 52 tryptamine derivative/ (2624) 53 triptan derivative/ (1999) 54 (tryptamin* or tryptomin* or triptan* or indolylethylamine* or NSC 73938 or NSC73938).tw,tn. (10838) 55 ("BRN 0125513" or CCRIS 8959 or EINECS 200-510-5 or Indol-3-ethylamine or UNII-422ZU9N5TV).tw,tn. (0) 56 61-54-1.rn. (2370) 57 almotriptan/ (997) 58 (almotriptan* or Almogran or Almotrex or Amignul or Axert or PNU 180638E or PNU-180638E or UNII- PJP312605E).tw,tn. (681) 59 154323-57-6.rn. (986) 60 eletriptan/ (1156) 61 (eletriptan* or Relpax or Relert or Relepax or "UK 116044" or "UK 116,044" or "UK-116044" or "UK-116,044" or UNII-22QOO9B8KI).tw,tn. (686) 62 143322-58-1.rn. (1135) 63 frovatriptan/ (792) 64 (frovatriptan* or Allegro or Frova or Frovelan or Migard or Miguard or SB 209509 or VML-251 or VML251).tw,tn. (927) 65 158747-02-5.rn. (764) 66 naratriptan/ (1470) 67 (naratriptan* or Amerge or Colatan or Naragran or Naramig or UNII-QX3KXL1ZA2).tw,tn. (841) 68 121679-13-8.rn. (1619) 69 rizatriptan/ (1928) 70 (rizatriptan* or Risatriptan* or "L 705,126" or "L 705126" or "L-705,126" or "L-705126" or Maxalt or "MK 0462" or MK 462 or MK-0462 or MK-462 or rizalief or rizalt or rizaliv or UNII-51086HBW8G).tw,tn. (1299) 71 144034-80-0.rn. (1881) 72 sumatriptan/ (8967) 73 (sumatriptan* or Arcoiran or Alsuma or BRN 6930870 or Diletan or Dolmigral or GR 43175 or GR 43175X or GR-43175 or HSDB 7742 or Imigran* or Imiject or Imitrex or micranil or Migril or Novelian or Sumigrene or Suminat or Sumatran or Sumatriptanum or Sumax or UNII-8R78F6L9VO or Zecuity).tw,tn. (6824) 74 103628-46-2.rn. (8795) 75 Zolmitriptan/ (2314) 76 (Zolmitriptan* or AscoTop or Flezol or Rapimelt or UNII-2FS66TH3YW or Zolmitriptan or Zomig or Zomig-ZMT or Zomigon or Zomigoro).tw,tn. (1407) 77 139264-17-8.rn. (2644) 78 naproxen plus sumatriptan succinate/ (23) 79 (Treximet or Trexima).tw,tn. (60) 80 811794-26-0.rn. (0) 81 or/52-80 (25720) Ontario Drug Policy Research Network Ontario Drug Policy Research Network 7 82 51 and 81 (10907) 83 randomized controlled trial/ (747726) 84 "randomized controlled trial (topic)"/ (39581) 85 Randomization/ (145233) 86 double blind procedure/ or single blind procedure/ or placebo/ (330971) 87 (random* or RCT$1 or placebo*).tw.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Intramuscular Tramadol Vs. Diclofenac Sodium for The
    J Headache Pain (2005) 6:143–148 DOI 10.1007/s10194-005-0169-y ORIGINAL Zulfi Engindeniz Intramuscular tramadol vs. diclofenac sodium Celaleddin Demircan Necdet Karli for the treatment of acute migraine attacks Erol Armagan in emergency department: a prospective, Mehtap Bulut Tayfun Aydin randomised, double-blind study Mehmet Zarifoglu Received: 6 February 2005 Abstract The aim of this prospec- injection in future visits. Any Accepted in revised form: 15 April 2005 tive, randomised, double-blind study adverse events, whether related to Published online: 13 May 2005 was to evaluate the efficacy of intra- the drug or not, were also recorded. muscular (IM) tramadol 100 mg in Patients were followed up by tele- emergency department treatment of phone 48 h later to check for any acute migraine attack and to com- headache recurrence. Two-hour pain pare it with that of IM diclofenac response rate, which was the prima- sodium 75 mg. Forty patients who ry endpoint, was 80% for both tra- were admitted to our emergency madol and diclofenac groups. There department with acute migraine were no statistically significant dif- attack according to the International ferences among groups in terms of Z. Engindeniz (౧) • E. Armagan • M. Bulut Headache Society criteria were 48-h pain response, rescue treat- T. Aydin Department of Emergency Medicine, included in the study. Patients were ment, associated symptoms’ Uludag University Medical Faculty, randomised to receive either tra- response, headache recurrence and Acil Tip ABD Gorukle, madol 100 mg (n=20) or diclofenac adverse event rates. Fifteen (75%) Bursa 16059, Turkey sodium 75 mg (n=20) intramuscular- patients in the tramadol group and e-mail: [email protected] ly.
    [Show full text]
  • ERJ-01090-2018.Supplement
    Shaheen et al Online data supplement Prescribed analgesics in pregnancy and risk of childhood asthma Seif O Shaheen, Cecilia Lundholm, Bronwyn K Brew, Catarina Almqvist. 1 Shaheen et al Figure E1: Data available for analysis Footnote: Numbers refer to adjusted analyses (complete data on covariates) 2 Shaheen et al Table E1. Three classes of analgesics included in the analyses ATC codes Generic drug name Opioids N02AA59 Codeine, combinations excluding psycholeptics N02AA79 Codeine, combinations with psycholeptics N02AA08 Dihydrocodeine N02AA58 Dihydrocodeine, combinations N02AC04 Dextropropoxyphene N02AC54 Dextropropoxyphene, combinations excluding psycholeptics N02AX02 Tramadol Anti-migraine N02CA01 Dihydroergotamine N02CA02 Ergotamine N02CA04 Methysergide N02CA07 Lisuride N02CA51 Dihydroergotamine, combinations N02CA52 Ergotamine, combinations excluding psycholeptics N02CA72 Ergotamine, combinations with psycholeptics N02CC01 Sumatriptan N02CC02 Naratriptan N02CC03 Zolmitriptan N02CC04 Rizatriptan N02CC05 Almotriptan N02CC06 Eletriptan N02CC07 Frovatriptan N02CX01 Pizotifen N02CX02 Clonidine N02CX03 Iprazochrome N02CX05 Dimetotiazine N02CX06 Oxetorone N02CB01 Flumedroxone Paracetamol N02BE01 Paracetamol N02BE51 Paracetamol, combinations excluding psycholeptics N02BE71 Paracetamol, combinations with psycholeptics 3 Shaheen et al Table E2. Frequency of analgesic classes prescribed to the mother during pregnancy Opioids Anti- Paracetamol N % migraine No No No 459,690 93.2 No No Yes 9,091 1.8 Yes No No 15,405 3.1 No Yes No 2,343 0.5 Yes No
    [Show full text]
  • The Serotonergic System in Migraine Andrea Rigamonti Domenico D’Amico Licia Grazzi Susanna Usai Gennaro Bussone
    J Headache Pain (2001) 2:S43–S46 © Springer-Verlag 2001 MIGRAINE AND PATHOPHYSIOLOGY Massimo Leone The serotonergic system in migraine Andrea Rigamonti Domenico D’Amico Licia Grazzi Susanna Usai Gennaro Bussone Abstract Serotonin (5-HT) and induce migraine attacks. Moreover serotonin receptors play an impor- different pharmacological preventive tant role in migraine pathophysiolo- therapies (pizotifen, cyproheptadine gy. Changes in platelet 5-HT content and methysergide) are antagonist of are not casually related, but they the same receptor class. On the other may reflect similar changes at a neu- side the activation of 5-HT1B-1D ronal level. Seven different classes receptors (triptans and ergotamines) of serotoninergic receptors are induce a vasocostriction, a block of known, nevertheless only 5-HT2B-2C neurogenic inflammation and pain M. Leone • A. Rigamonti • D. D’Amico and 5HT1B-1D are related to migraine transmission. L. Grazzi • S. Usai • G. Bussone (౧) syndrome. Pharmacological evi- C. Besta National Neurological Institute, Via Celoria 11, I-20133 Milan, Italy dences suggest that migraine is due Key words Serotonin • Migraine • e-mail: [email protected] to an hypersensitivity of 5-HT2B-2C Triptans • m-Chlorophenylpiperazine • Tel.: +39-02-2394264 receptors. m-Chlorophenylpiperazine Pathogenesis Fax: +39-02-70638067 (mCPP), a 5-HT2B-2C agonist, may The 5-HT receptor family is distinguished from all other 5- Introduction 1 HT receptors by the absence of introns in the genes; in addi- tion all are inhibitors of adenylate cyclase [1]. Serotonin (5-HT) and serotonin receptors play an important The 5-HT1A receptor has a high selective affinity for 8- role in migraine pathophysiology.
    [Show full text]
  • Antimigraine Agents, Triptans Review 07/21/2008
    Antimigraine Agents, Triptans Review 07/21/2008 Copyright © 2004 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended
    [Show full text]
  • Frovatriptan Versus Zolmitriptan for the Acute Treatment of Migraine: a Double-Blind, Randomized, Multicenter, Italian Study
    Neurol Sci (2010) 31 (Suppl 1):S51–S54 DOI 10.1007/s10072-010-0273-x SYMPOSIUM: NEWS IN TREATMENT OF MIGRAINE ATTACK Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study Vincenzo Tullo • Gianni Allais • Michel D. Ferrari • Marcella Curone • Eliana Mea • Stefano Omboni • Chiara Benedetto • Dario Zava • Gennaro Bussone Ó The Author(s) 2010. This article is published with open access at Springerlink.com Abstract The objective of this study is to assess patients’ of PF episodes at 2 h was 26% with F and 31% with Z satisfaction with migraine treatment with frovatriptan (F) (p = NS). PR episodes at 2 h were 57% for F and 58% for or zolmitriptan (Z), by preference questionnaire. 133 sub- Z(p = NS). Rate of recurrence was 21 (F) and 24% jects with a history of migraine with or without aura (IHS (Z; p = NS). Time to recurrence within 48 h was better for criteria) were randomized to F 2.5 mg or Z 2.5 mg. The F especially between 4 and 16 h (p \ 0.05). SPF episodes study had a multicenter, randomized, double-blind, cross- were 18 (F) versus 22% (Z; p = NS). Drug-related adverse over design, with each of the two treatment periods lasting events were significantly (p \ 0.05) less under F (3 vs. 10). no more than 3 months. At the end of the study, patients In conclusion, our study suggests that F has a similar were asked to assign preference to one of the treatments efficacy of Z, with some advantage as regards tolerability (primary endpoint).
    [Show full text]
  • Acute Migraine Treatment
    Acute Migraine Treatment Morris Levin, MD Professor of Neurology Director, Headache Center UCSF Department of Neurology San Francisco, CA Mo Levin Disclosures Consulting Royalties Allergan Oxford University Press Supernus Anadem Press Amgen Castle Connolly Med. Publishing Lilly Wiley Blackwell Mo Levin Disclosures Off label uses of medication DHE Antiemetics Zolmitriptan Learning Objectives At the end of the program attendees will be able to 1. List all important options in the acute treatment of migraine 2. Discuss the evidence and guidelines supporting the major migraine acute treatment options 3. Describe potential adverse effects and medication- medication interactions in acute migraine pharmacological treatment Case 27 y/o woman has suffered ever since she can remember from “sick headaches” . Pain is frontal, increases over time and is generally accompanied by nausea and vomiting. She feels depressed. The headache lasts the rest of the day but after sleeping through the night she awakens asymptomatic 1. Diagnosis 2. Severe Headache relief Diagnosis: What do we need to beware of? • Misdiagnosis of primary headache • Secondary causes of headache Red Flags in HA New (recent onset or change in pattern) Effort or Positional Later onset than usual (middle age or later) Meningismus, Febrile AIDS, Cancer or other known Systemic illness - Neurological or psych symptoms or signs Basic principles of Acute Therapy of Headaches • Diagnose properly, including comorbid conditions • Stratify therapy rather than treat in steps • Treat early
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • CP.CPA.217 Triptans.Pdf
    Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.20 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are triptans requiring prior authorization and/or quantity limits: naratriptan (Amerge®), almotriptan (Axert®), frovatriptan (Frova®), sumatriptan (Imitrex®, Tosymra™), rizatriptan (Maxalt®/Maxalt-MLT®), eletriptan (Relpax®), sumatriptan/naproxen (Treximet®), zolmitriptan (Zomig®/Zomig® ZMT), Imitrex® injection, Onzetra™ Xsail™, Sumavel™ Dosepro™, and Zembrace™ SymTouch™. FDA Approved Indication(s) Triptans are indicated for the acute treatment of migraine attacks with or without aura in: • Adults (all products) • Pediatric patients (certain products only): o Axert: age 12 to 17 years with a history of migraine attacks usually lasting 4 hours or more (when untreated) o Maxalt, Maxalt MLT: age 6 to 17 years old o Treximet, Zomig Nasal Spray: age 12 to 17 years Imitrex injection and Sumavel DosePro are additionally indicated for the treatment of acute treatment of cluster headache in adults. Limitation(s) of use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with a specific triptan, reconsider the diagnosis of migraine before that triptan is administered to treat any subsequent attacks. • Triptans are not indicated for the prevention of migraine attacks. • All triptans except Imitrex injection and Sumavel DosePro: safety and effectiveness of triptans have not been established for cluster headache. • Imitrex injection and Sumavel DosePro: not indicated for the preventative treatment of cluster headache attacks.
    [Show full text]
  • Zomig and Zomig Rapimelt Are Trade Marks of the Astrazeneca Group of Companies
    AUSTRALIAN PRODUCT INFORMATION Zomig® and Zomig Rapimelt® (zolmitriptan) 1 NAME OF THE MEDICINE Zolmitriptan 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Zomig is presented as round, yellow (2.5 mg) or pink (5 mg), biconvex film-coated intagliated (with a ‘Z’ on one side) tablets containing 2.5 mg or 5 mg zolmitriptan. The 2.5 mg tablets are 7.4 mm in diameter and are compressed to a weight of 122 mg. The 5 mg tablets are 8.6 mm in diameter and are compressed to a weight of 244 mg. Zomig Rapimelt is presented as orally dispersible white round uncoated orange flavoured tablets containing 2.5 mg zolmitriptan. The tablets are 6.4 mm in diameter, flat-faced with a bevelled edge and intagliated with ‘Z’ on one side. The tablets are compressed to a weight of 100 mg. Excipient(s) with known effect: lactose monohydrate (Zomig), aspartame (Zomig Rapimelt). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM • Tablet, film-coated • Tablet, dispersible (oral) 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zomig is indicated for the acute treatment of migraine with or without aura. 4.2 DOSE AND METHOD OF ADMINISTRATION The recommended initial dose of Zomig to treat a migraine attack is 2.5 mg. The Zomig conventional tablet should be swallowed whole with water. The Zomig Rapimelt orally dispersible tablet rapidly dissolves when placed on the tongue and is swallowed with the patient’s saliva. A drink of water is not required when taking the Zomig Rapimelt orally dispersible tablet.
    [Show full text]
  • Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized Via Quality by Design Approach
    Scientia Pharmaceutica Article Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized via Quality by Design Approach Asmaa Saleh 1, Maha Khalifa 2 , Seham Shawky 2, Amjaad Bani-Ali 3 and Heba Eassa 2,* 1 Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; [email protected] 2 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo 11651, Egypt; [email protected] (M.K.); [email protected] (S.S.) 3 Pharmacy Practice Department, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; [email protected] * Correspondence: [email protected]; Tel.: +20-114-261-2925 Abstract: Zolmitriptan is a potent second-generation triptan prescribed for migraine attacks. It suffers low bioavailability (40%) after oral administration due to the hepatic first-pass metabolism. Spanlastics are surfactant-based elastic vesicular drug carrier systems. This study aimed to design and optimize intranasal spanlastic formulations as an alternative approach that directly targets brain delivery, enhancing its bioavailability and avoiding the first-pass effect. The quality by design approach was applied to correlate the formulation parameters (Span 60 and Tween 80 concentrations) and critical quality attributes (entrapment efficiency (EE%) and particle size). Spanlastic formulations Citation: Saleh, A.; Khalifa, M.; were designed based on response surface central composite design and prepared via an ethanol injec- Shawky, S.; Bani-Ali, A.; Eassa, H. tion method. Designed formulations were characterized by EE% and particle size measurements to Zolmitriptan Intranasal Spanlastics select the optimized formula (with a combination of small particle size and high EE%).
    [Show full text]